A patient-based study characterized NLRP3 in the first stages of midbrain nigral neurodegeneration and in the biofluids drawn from PD patients, suggesting that NLRP3 may be both a key inflammation mediator in the degenerating midbrain and a tractable therapeutic target [385]. The gene discussed is NLRP3; the disease is Parkinson disease.